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We observed large variations in the activity of lactate dehydrogenase (EC 1.1.1.27) in serum when random lots of NADH were used in its determination. The imprecision, caused by variable amounts of lactate dehydrogenase inhibitor in the NADH preparations, was greatly lessened by using only a single lot of NADH; reliability was improved further by selecting an NADH preparation having a negligible amount of inhibitor.
A method is described for assessing the quality of commercial NADH preparations, so as to have a satisfactory reagent and to maintain continuously comparable results over an extended period of time. The results have possible relevance for proposed governmental regulation of commercial kits and reagents used for clinical laboratory testing, and for improved intra-and inter-laboratory comparability of lactate dehydrogenase determinations.
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The presence of a powerful inhibitor of LD3 in commercial NADH preparations has been recognized for many years (1) (2) (3) (4) . Because the amount of inhibitor varies greatly from lot to lot of NADH (4), reliability of the LD determination in clinical laboratories may be severely compromised.
The significance of this inhibitor for the accuracy, precision, and clinical usefulness of LD determinations needs further emphasis.
We describe here our long-term experience with several lots of "high purity" commercial NADH, and how changes of lots affected the accuracy and precision of the LD assay and caused changes in the apparent normal range. We propose a method to assure the analytical reliability of LD determinations. 
Materials and Methods

Results
Proficiency Data
Proficiency data for more than four consecutive years for the supranormal control serum samples are summarized in Figure 1 . The other control sera (normal and moderately elevated) showed essentially the same results.
During the first two years (1968) (1969) (1970) ) the procedure was performed manually and unselected lots of NADH were used. During the third year (1970-71) the procedure was automated and, in addition, a single lot of NADH was used during the entire year. These changes caused the standard deviation of the annual mean to decrease from 27 during 1969-70 to 11 during the first 11 months of 1970-71. In September of 1970-71, a new lot of NADH was used, resulting in an abrupt increase of approximately 20% in the monthly mean ( Figure 1) . Unfortunately, at the same time when the new order for NADH was placed, the necessity for a single lot was not stipulated in the contract.
Thus, in the fourth year Peak IV is quite small in Figure 2 (top), but considerably larger in Figure 2 (bottom). The spectrum of pooled fractions of peak IV, shown in Figure 3 , is identical to that of an LD inhibitor described by Strandjord and Clayson
(2), which formed in frozen alkaline solutions of NADH. LD inhibitory activity was demonstrated in peak IV by determining the LD activity of a reference serum with use of (a) unfractionated NADH, (b) the chromatographically purified NADH peak, and (c) the latter with peak IV fractions added to it. Figure   4 , which summarizes six experiments, shows that this NADH preparation contained enough LD inhibitor to diminish enzyme activity by 16%. point is a monthly mean of a supranormal control serum, and the standard deviation is shown. Each row of points represents a period of about one year during which a single lot of control serum was used. The manufacturer's calculated ("target") activity0 for each control serum is indicated by the horizontal line for each year. To the right of each annual plot is the range of monthly means, and the standard deviation of the annual mean; this gives an indication of the precision attained during the entire year. For the third period , the data for September 1971 were excluded from the calculation of the range of monthly means and the standard deviation of the annual mean ELUATE, ml and methods for LD determination are based on either the forward (as shown here) (5, 6) or reverse (9) reaction.
We prefer to use the forward reaction,4 in which NADH is used as a reagent, and the determination is made by measuring the decrease in absorbance at 340 nm as NADH is consumed. However, the reverse reaction is also widely used, primarily because it is readily adaptable, by a variety of means (12) (13) (14) , to absorbance measurements in the visible range and consequently analyses can be made with less-expensive instrumentation that is available to most clinical laboratories.
Regardless of how the measurement is made, the determination is an important diagnostic and prognostic aid, particularly in evaluating patients suspected of having coronary heart disease (16). In such patients, borderline elevations have clinical significance (17) and clinicians are especially attentive both to the initial serum LD level, and subsequent serial increases or decreases in LD activity.
The primary base of reference for the clinical interpretation of laboratory data is the laboratory's stated normal range.
The 
